[go: up one dir, main page]

DK3126351T3 - Biarylkinasehæmmere - Google Patents

Biarylkinasehæmmere Download PDF

Info

Publication number
DK3126351T3
DK3126351T3 DK15717342.8T DK15717342T DK3126351T3 DK 3126351 T3 DK3126351 T3 DK 3126351T3 DK 15717342 T DK15717342 T DK 15717342T DK 3126351 T3 DK3126351 T3 DK 3126351T3
Authority
DK
Denmark
Prior art keywords
oxy
amine
dimethylpentan
methyl
pyridin
Prior art date
Application number
DK15717342.8T
Other languages
English (en)
Inventor
Guanglin Luo
Carolyn Diane Dzierba
Jonathan L Ditta
John E Macor
Joanne J Bronson
Ling Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3126351T3 publication Critical patent/DK3126351T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/18—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member containing only hydrogen and carbon atoms in addition to the ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (14)

  1. BIARYLKINASEHÆMMERE
    1. Forbindelse med formlen (I)
    (I), eller et farmaceutisk acceptabelt salt deraf, hvor: A er valgt fra
    hvor '
    ' betegner bindingspunktet til B; B er valgt fra
    hvor indikerer bindingspunktet til R5 og "**" indikerer bindingspunktet til ring A; R1 er valgt fra hydrogen, amino, -CO2H, difluormethyl, ethyl, halo, hydroxymethyl, methoxy, methyl, -NHC(O)CH3, -NHCO2CH3, trifluormethoxy og trifluormethyl; R2 er valgt fra hydrogen, cyano, -CH2OH, halo og methyl; R3 er valgt fra hydrogen, cyano, cyclopropyl, difluormethyl, halo, hydroxymethyl, methoxy, methyl, methylsulfonyl, trifluormethoxy, trifluormethyl, -CH2N(CH3)2, og en femleddet aromatisk ring, der indeholder ét, to eller tre heteroatomer valgt fra nitrogen, oxygen og svovl; R4 er valgt fra hydrogen, halo og methyl; R5 er valgt fra
    R6 er valgt fra hydrogen, ethyl, fluormethyl, difluormethyl, methyl og trifluormethyl; og R7 er methyl.
  2. 2. Forbindelse ifølge krav 1, eller et farmaceutisk acceptabelt salt deraf, hvor A er valgt fra
  3. 3. Forbindelse ifølge krav 1, eller et farmaceutisk acceptabelt salt deraf, hvor B er valgt fra
  4. 4. Forbindelse ifølge krav 3, eller et farmaceutisk acceptabelt salt deraf, hvor B er
  5. 5. Forbindelse ifølge krav 1, hvor R5 er
  6. 6. Forbindelse ifølge krav 1, der er valgt fra (5)-2V-(4-(4-((2-amino-4-methylpentyl)oxy)-3-fluorphenyl)pyridin-2-yl)acetamid; (5)-2V-(4-(4-((2-amino-4-methylpentyl)oxy)-3-methoxyphenyl)pyridin-2-yl)acetamid; (5)-2V-(4-(4-((2-amino-4-methylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)ace tamid; (5)-2-((2-amino- 4- methylpentyl)oxy)-5-(2-aminopyridin-4-yl)benzonitril; (5)-ZV-(4-(4-((2-amino-4-methylpentyl)oxy)-3-(trifluormethyl)phenyl)pyridin-2-yl)acetamid; (5)-ZV-(4-(4-((2-amino-4-methylpentyl)oxy)-3-(trifluormethoxy)phenyl)pyridin-2-yl)acetamid; (5)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3-methylphenyl)pyridin-2-yl)acetamid; (5)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3-chlorphenyl)pyridin-2-yl)acetamid; (5)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3,5-difluorphenyl)pyridin-2-yl)acetamid; (5)-ZV-(4-(4-((2-amino-4-methylpentyl)oxy)-3-chlor-5-fluorphenyl)pyridin-2-yl)ace tamid; (5)-ZV-(4-(4-((2-amino-4-methylpentyl)oxy)-3-fluor-5-(trifluormethyl)phenyl)pyridin-2- yl)acetamid; (5)-ZV-(4-(4-((2-amino-4-methylpentyl)oxy)-2,5-difluorphenyl)pyridin-2-yl)acetamid; (5)-methyl (4-(4-((2-amino-4-methylpentyl)oxy)-3-fluorphenyl)pyridin-2-yl)carbamat; (5)-methyl (4-(4-((2-amino-4-methylpentyl)oxy)-3-(isoxazol-5-yl)phenyl)pyridin-2-yl)carbamat; (5)-2-((2-amino-4-methylpentyl)oxy)-5-(2-methylpyridin-4-yl)benzonitril; (5)-2-((2-amino- 4- methylpentyl)oxy)-5-(2-methoxypyridin-4-yl)benzonitril; (5)-2-((2-amino- 4- methylpentyl)oxy)-5-(2-(trifluormethyl)pyridin-4-yl)benzonitril; (5)-l-(2-(isoxazol-5-yl)-4-(2-methylpyridin-4-yl)phenoxy)-4-methylpentan-2-amin; (5)-ZV-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluormethyl)phenyl)pyridin-2-yl)acetamid; (5)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluormethyl)phenyl)pyridin-2- yl)carbamat;
    (5)-ZV-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)acetamid; (5)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)carbamat; (5)-ZV-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(difluormethyl)phenyl)pyridin-2-yl)acetamid; (5)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(difluormethyl)phenyl)pyridin-2- yl)carbamat; (5)-ZV-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluormethoxy)phenyl)pyridin-2-yl)acetamid; (5)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluormethoxy)phenyl)pyridin-2- yl)carbamat; (5)-ZV-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorphenyl)pyridin-2-yl)acetamid; (5)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-fluorphenyl)pyridin-2-yl)carbamat; methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorphenyl)pyridin-2-yl)carbamat; methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-methylphenyl)pyridin-2-yl)carbamat; methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-2,3-dimethylphenyl)pyridin-2-yl)carbamat; (Si-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(hydroxymethyl)phenyl)pyridin-2- yl)carbamat; (Si-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-cyclopropylphenyl)pyridin-2-yl)carbamat; (5)-ZV-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluormethyl)phenyl)-5- (hydroxymethyl)pyridin-2-yl)acetamid; (5)-l-(4-(2-(difluormethyl)pyridin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-2-((2-amino- 2,4-dimethylpentyl)oxy)-5-(2-(difluormethyl)pyridm-4-yl)benzonitril; (5)-l-(2-(difluormethyl)-4-(2-(difluormethyl)pyTidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(2-(difluormethyl)pyridin-4-yl)-2-(trifluormethoxy)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(3-chlor-2-fluorpyridin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(5-chlor-2-fluorpyridin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(2-fluor-3-methylpyTidin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(2,3-difluorpyridin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-2,4-dimethyl-l-(4-(pyridin-4-yl)-2-(trifluormethyl)phenoxy)pentan-2-amin; (5)-l-(4-(2-fluorpyTidin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-2,4-dimethyl-l-(4-(2-methylpyTidin-4-yl)-2-(trifluormethyl)phenoxy)pentan-2-amin; (5)-l-(4-(3-methoxypyridin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(3-fluorpyTidin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-2-((2-amino- 2,4-dimethylpentyl)oxy)-5-(2-methylpyridin-4-yl) be nzonitril; (5)-l-(2-cyclopropyl-4-(2-methylpyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(2-(difluormethyl)-4-(2-methylpyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-[3,4'-bipyridin]-2'-yl)carbamat; (5)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-5-methyl-[3,4'-bipyridin]-2'-yl)carbamat; (5)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-5-cyano-[3,4'-bipyridin]-2'-yl)carbamat; (5)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-4-methyl-[3,4'-bipyridin]-2'-yl)carbamat; (5)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-5-chlor-[3,4'-bipyridin]-2'-yl)carbamat; (5)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-5-methoxy-[3,4'-bipyridin]-2'-yl)carbamat; (S)-l-((2'-chlor-5-methyl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((2'-(difluormethyl)-5-methyl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-6-((2-amino-2,4-dimethylpentyl)oxy)-2'-(difluormethyl)-[3,4'-bipyridine]-5-carbonitril; (5)-l-((5-chlor-2'-methyl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((2',5-dimethyl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((5-methoxy-2'-methyl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-[2,4'-bipyridin]-2'-yl)carbamat; (5)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-6-methyl-[2,4'-bipyridin]-2'-yl)carbamat; (5)-l-((2',6-dimethyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-6-chlor-[2,4'-bipyridin]-2'-yl)carbamat; (5)-l-((6-chlor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4-methyl-[2,4'-bipyridin]-2'-yl)carbamat; (5)-2,4-dimethyl-l-(4-(quinolin-4-yl)-2-(trifluormethyl)phenoxy)pentan-2-amin; (5)-2,4-dimethyl-l-(2-(trifluormethyl)-4-(7-(trifluormethyl)quinolin-4-yl)phenoxy)pentan-2-amin; (5)-l-(4-(7-fluorquinolin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(5,7-difluorquinolin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(6-fluorquinolin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(2-cyclopropyl-4-(quinolin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; l-(2-chlor-6-fluor-4-(quinolin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-((5-(7-fluorquinolin-4-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(5,7-difluorquinolin-4-yl)nicotinoni tril; (5)-l-((3-chlor-5-(quinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((3-methoxy-5-(quinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-2-((2-amino- 2,4-dimethylpentyl)oxy)-5-(l,6-naphthyridin-4-yl)nicotinonitril; (5)-2,4-dimethyl-l-((2-methyl-6-(quinolin-4-yl)pyridin-3-yl)oxy)pentan-2-amin; (5)-2,4-dimethyl-l-((4-methyl-6-(quinolin-4-yl)pyridin-3-yl)oxy)pentan-2-amin; (5)-l-((2-chlor-6-(quinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(lZ/-pyrrolo[2,3-fc]pyridin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(l,6-naphthyridin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(l,6-naphthyridin-4-yl)benzoni tril; (5)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(l,5-naphthyridin-4-yl)benzoni tril; (5)-l-(4-(7-chlorquinolin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluormethyl)phenyl)quinoline-7-carboni tril; (5)-2,4-dimethyl-l-(2-methyl-4-(2-methylpyridin-4-yl)phenoxy)pentan-2-amin; (5)-l-(2-fluor-4-(2-methylpyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(4-(2-fluorpyridin-4-yl)-2-methylphenoxy)-2,4-dimethylpentan-2-amin; (5)-l-(2-fluor-4-(2-fluorpyridin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-2-((2-amino- 2,4-dimethylpentyl)oxy)-5-(2-fluorpyridin-4-yl)benzonitril; (5)-l-((2'-fluor-5-methyl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-4-(6-((2-amino-2,4-dimethylpentyl)oxy)-5-methylpyridin-3-yl)quinoline-7-carbonitril; (5)-l-((5-fluor-2'-methyl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((3-fluor-5-(quinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-4-(6-((2-amino-2,4-dimethylpentyl)oxy)-5-fluorpyridin-3-yl)quinoline-7-carbonitril; (5)-methyl (4-(4-((2-amino-2,4-dimeth ylpentyl)oxy)-3-cyanophenyl)-3-fluorpyridin-2- yl)carbamat; (5)-6-((2-amino- 2,4-dimethylpentyl)oxy)-2'-methyl-[3,4'-bipyridine]-5-carbonitril; (5)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(7-methylquinolin-4-yl)benzonitril; (5)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(3-fluor-2-methylpyri din-4-yl)benzoni tril; (5)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(quinolin-4-yl)benzoni tril; (5)-2-((2-amino-2,4-dimethylpentyl)oxy)-5-(5-fluor-2-methylpyri din-4-yl)benzoni tril; (5)-methyl (4-(4-((2-amino-2,4-dimeth ylpentyl)oxy)-3-cyanophenyl)-5-fluorpyridin-2- yl)carbamat; (5)-l-((6-fluor-2',4-dimethyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; methyl (5-((3-isobutylazetidin-3-yl)methoxy)-6-methyl-[2,4'-bipyridin]-2'-yl)carbamat; (5)-2-((2-amino-4-methylpentyl)oxy)-5-(6-methylpyridazin-4-yl)benzonitril; (5)-l-(2-(isoxazol-5-yl)-4-(quinolin-4-yl)phenoxy)-4-methylpentan-2-amin; (5)-4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluormethyl)phenyl)-2-methylnicotinsyre; (5)-methyl(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-((dimethylamino)methyl)phenyl)pyridin-2- yl)carbamat; (5)-methyl(4-(4-((2-amino-2,4-dimeth ylpentyl)oxy)-3-(methylsulfonyl)phenyl)pyridin-2-yl)carbamat; (5)-2,4-dimethyl-l-(4-(2-methylpyridin-4-yl)-2-(methylsulfonyl)phenoxy)pentan-2-amin; (5)-2,4-dimethyl-l-(2-(methylsulfonyl)-4-(quinolin-4-yl)phenoxy)pentan-2-amin; (5)-l-(2-(difluormethyl)-4-(6-fluorquinolin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-methyl (5-((2-amino-2,4-dimeth ylpentyl)oxy)-6-(difluormethyl)-[2,4'-bipyridin]-2'- yl)carbamat; (5)-l-((2-(difluormethyl)-6-(quinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((6-(difluormethyl)-2'-meth yl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4-(difluormethyl)-[2,4'-bipyridin]-2'- yl)carbamat; (S)-l-((4-(difluormethyl)-6-(quinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((4-(difluormethyl)-2'-methyl-[2,4'-bipyTidin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((2',6-bis(difluormethyl)-[2,4'-bipyridin] -5-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((2',4-bis(difluormethyl)-[2,4'-bipyTidin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((2'-(difluormethyl)-4-methyl-[2,4'-bipyTidin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-(2-cyclopropyl-4-(2-(difluormethyl)pyTidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; (S)-l-((2-(difluormethyl)-6-(6-fluorqumolin-4-yl)pyridm-3-yl)oxy)-2,4-dimethylpentan-2-amm; (S)-l-((2-(difluormethyl)-6-(7-fluorqumolin-4-yl)pyridm-3-yl)oxy)-2,4-dimethylpentan-2-amm; (S)-l-((2-(difluormethyl)-6-(5,7-difluorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2- amin; (S)-l-((4-(difluormethyl)-6-(5,7-difluorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2- amin; (S)-l-((4-(difluormethyl)-6-(7-fluorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((4-(difluormethyl)-6-(6-fluorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; ((S)-l-((4-(difluormethyl)-6-(6-(trifluormethyl)quinolin-4-yl)pyridin-3-yl)oxy)-2,4- dimethylpentan- 2- amin; (S)-l-((4-(difluormethyl)-6-(6-(trifluormethoxy)quinolin-4-yl)pyTidin-3-yl)oxy)-2,4-dimethylpentan- 2- amin; (S)-l-((2-chlor-6-(5,7-difluorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((2-chlor-6-(7-fluorqumolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((6-(7-fluorquinolin-4-yl)-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((6-(6-fluorquinolin-4-yl)-2-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((2-(difluormethyl)-6-(2-methylpyrimidin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2- amin; (S)-l-((2-(difluormethyl)-6-(6-methylpyrimidin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2- amin; (S)-l-((4-(difluormethyl)-2'-ethyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amm; (S)-l-((2'-chlor-4-(difluormethyl)-3'-fluor-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((2'-chlor-4-(difluormethyl)-5'-fluor-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-2,4-dimethyl-l-((2'-methyl-4-(trifluormethyl)-[2,4'-bipyTidin]-5-yl)oxy)pentan-2-amin; (S)-2,4-dimethyl-l-((6-(quinolin-4-yl)-4-(trifluormethyl)pyTidin-3-yl)oxy)pentan-2-amin; (S)-methyl(5-((2-amino-2,4-dimethylpentyl)oxy)-4-(trifluormethyl)-[2,4'-bipyTidin]-2'- yl)carbamat; (S)-l-((2'-chlor-4-(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((4-(difluormethyl)-5'-fluor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (S)-l-((4-(difluormethyl)-3'-fluor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-(difluormethyl)-6-(2-methylpyrimidin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2- amin; (5)-l-(2-(difluormethyl)-4-(2-methylpyrimidin-4-yl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-5-((2-amino-2,4-dimethylpentyl)oxy)-3'-fluor-6-methyl-[2,4'-bipyridin]-2'-amin; (5)-l-((2'-chlor-3'-fluor-6-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl(5-((2-amino-2,4-dimethylpentyl)oxy)-5'-fluor-6-methyl-[2,4'-bipyridin]-2'-yl)carbamat; (5)-l-((2'-chlor-5'-fluor-6-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-3'-fluor-6-methyl-[2,4'-bipyridin]-2'- yl)carbamat; (5)-l-((2'-chlor-6-(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((2'-chlor-6-(difluormethyl)-3'-fluor-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpen tan-2-amin; (5)-l-((6-(difluormethyl)-3'-fluor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; ((5)-l-((6-chlor-2'-(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-(difluormethyl)-6-(6-methylpyridazin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((2-(difluormethyl)-6-(6-methylpyridazin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (R)-2,4-dimethyl-l-((2'-methyl-4-(trifluormethyl)-[2,4'-bipyridin] -5-yl)oxy)pentan-2-amin; (R)-2,4-dimethyl-l-((6-(quinolin-4-yl)-4-(trifluormethyl)pyridin-3-yl)oxy)pentan-2-amin; (R)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4-(trifluormethyl)-[2,4'-bipyridin]-2'- yl)carbamat; (R)-l-((2'-chlor-4-(difluormethyl)-3'-fluor-[2,4'-bipyridm]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (R)-l-((2'-chlor-4-(difluormethyl)-5'-fluor-[2,4'-bipyridm]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (R)-l-((2'-chlor-4-(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (R)-l-((4-(difluormethyl)-2'-ethyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (R)-l-((4-(difluormethyl)-5'-fluor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amm; (R)-l-((4-(difluormethyl)-3'-fluor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (R)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-6-methyl-[2,4'-bipyridin]-2'-yl)carbamat; (/?)-1-((2)6-bis(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (R)-l-((2)4-bis(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl (4-(difluormethyl)-5-((2-hydroxy-2,4-dimethylpentyl)oxy)-[2,4'-bipyridin]-2'- yl)carbamat; (5)-l-((4-(difluormethyl)-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-ol; (5)-methyl (5-((2-amino-2-(fluormethyl)-4-methylpentyl)oxy)-6-(difluormethyl)-[2,4'-bipyridin]- 2'-yl)carbamat; (R)-methyl (5-((2-amino-2-(fluormethyl)-4-methylpentyl)oxy)-6-(difluormethyl)-[2,4'-bipyridin]-2'-yl)carbamat; (5)-methyl (5-((2-amino-2-(fluormethyl)-4-methylpentyl)oxy)-4-(difluormethyl)-[2,4'-bipyridin]-2'-yl)carbamat; (R)-methyl (5-((2-amino-2-(fluormethyl)-4-methylpentyl)oxy)-4-(difluormethyl)-[2,4'-bipyridin]-2'-yl)carbamat; (5)-l-((2',6-bis(difluormethyl)-[2,4'-bipyridin] -5-yl)oxy)-2-(fluormethyl)-4-meth ylpentan-2-amin; (5)-l-((2',4-bis(difluormethyl)-[2,4'-bipyridin] -5-yl)oxy)-2-(fluormethyl)-4-meth ylpentan-2-amin; (R)-l-((2',6-bis(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2-(fluormethyl)-4-methylpentan-2-amin; (R)-l-((2',4-bis(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2-(fluormethyl)-4-methylpentan-2-amin; (5)-l-((4-(difluormethyl)-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2-(fluormethyl)-4-methylpentan-2- amin; (R)-l-((4-(difluormethyl)-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2-(fluormethyl)-4-methylpentan-2- amin; (5)-2V-(4-(4-((2-amino-4-methylpentyl)oxy)-3-fluorphenyl)pyridin-2-yl)acetamid; (5)-l-((3-chlor-5-(7-fluorquinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((3-chlor-5-(6-fluorquinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((3-chlor-5-(2-methylpyrimidin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((2'-chlor-5-(difluormethyl)-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((5-(difluormethyl)-2'-meth yl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((3-(difluormethyl)-5-(7-fluorquinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl (6-((2-amino-2,4-dimeth ylpentyl)oxy)-5-(difluormethyl)-[3,4'-bipyridin]-2'- yl)carbamat; (5')-l-((5-(7-chlorquinolin-4-yl)-3-(difluormethyl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((3-(difluormethyl)-5-(2-methylpyrimidin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2- amin; (5)-l-((2',5-bis(difluormethyl)-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((3-(difluormethyl)-5-(6-lluorquinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((3-(difluormethyl)-5-(5,7-difluorquinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2- amin; (5)-l-((3-(difluormethyl)-5-(7-(trifluormethyl)quinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan- 2-amin; (5)-l-((5-(difluormethyl)-2',3'-dimethyl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((3-(difluormethyl)-5-(quinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((3-(difluormethyl)-5-(7-methylquinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4-methoxy-[2,4'-bipyridin]-2'-yl)carbamat; (5)-l-((2'-(dilluormethyl)-4-methoxy-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)naphthalen-l-yl)pyridin-2-yl)carbamat; (5)-2,4-dimethyl-l-((4-(quinolin-4-yl)naphth alen-l-yl)oxy)pentan-2-amin; (5)-methyl (4-(5-((2-amino-2,4-dimethylpentyl)oxy)pyrimidin-2-yl)pyridin-2-yl)carbamat; (5)-methyl (4-(2-((2-amino-2,4-dimethylpentyl)oxy)pyrimidin-5-yl)pyridin-2-yl)carbamat; (5)-2,4-dimethyl-1-((2)4,6- trimethyl-[2,4 '-bipyridin]-5-yl)oxy)pentan-2-amin; (5)-methyl(5-((2-amino-2,4-dimethylpentyl)oxy)-4,6-dimethyl-[2,4'-bipyridin]-2'-yl)carbamat; (5)-2,4-dimethyl-l-(4-(quinazolin-4-yl)-2-(trifluormethyl)phenoxy)pentan-2-amin; (5)-l-(4-(3,6-dihydro-2H-pyran-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-2,4-dimethyl-l-(4-(2-methylquinolin-4-yl)-2-(trifluormethyl)phenoxy)pentan-2-amin; (5)-l-(4-(6-chlorquinolin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimethylpentan-2-amin; (5)-l-((5-(5,7-difluorquinolin-4-yl)-3-(trifluormethyl)pyTidin-2-yl)oxy)-2,4-dimethylpentan-2- amin; (5)-2,4-dimethyl-l-((5-(quinolin-4-yl)-3-(trifluormethyl)pyridin-2-yl)oxy)pentan-2-amin; (5)-methyl (6-((2-amino-2,4-dimeth ylpentyl)oxy)-5-(trifluormethyl)-[3,4'-bipyridin]-2'- yl)carbamat; (5)-2,4-dimethyl-l-((2'-methyl-5-(trifluormethyl)-[3,4'-bipyridin]-6-yl)oxy)pentan-2-amin; (5)-l-((5-(6-chlorquinolin-4-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((5-(6-fluorquinolin-4-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((5-(5,7-difluorquinolin-4-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((5-(7-chlorquinolin-4-yl)-3-methylpyridin-2-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((6-(5,7-difluorquinolin-4-yl)-4-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((6-(7-fluorquinolin-4-yl)-4-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((2)4-dimethyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((6-(6-chlorquinolin-4-yl)-4-methylpyridin-3-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((6-(6-fluorquinolin-4-yl)-4-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((6-(7-chlorquinolin-4-yl)-4-methylpyridin-3-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((6-(7-fluorquinolin-4-yl)-4-methylpyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-chlor-6-(5,7-difhiorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-chlor-[2,4'-bipyridin] -5-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((4-chlor-6-(6-fluorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-chlor-6-(quinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4-chlor-[2,4'-bipyridin]-2'-yl)carbamat; (5)-l-((4-chlor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-chlor-6-(6-chlorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-1-((2)4-dichlor-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-chlor-6-(7-fluorquinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-chlor-6-(7-(trifluormethyl)quinolin-4-yl)pyridin-3-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((4-chlor-2)3'-dimethyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((5-(difluormethyl)-2'-meth yl-[3,4'-bipyridin]-6-yl)oxy)-2,4-dimeth ylpentan-2-amin; (R)-methyl (6-((2-amino-2,4-dimeth ylpentyl)oxy)-5-(difluormethyl)-[3,4'-bipyridin]-2'- yl)carbamat; (Λ)- l-((3-(difluormethyl)-5-(quinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2- amin; (R)-l-((3-(difluormethyl)-5-(2-methylpyrimidin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2- amin; (Æ)- l-((3-(difluormethyl)-5-(5,7-difluorquinolin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2- amin; og (R) -l-((5-(7-chlorquinolin-4-yl)-3-(difluormethyl)pyridin-2-yl)oxy)-2,4-dimethylpentan-2-amin; eller et farmaceutisk acceptabelt salt deraf.
  7. 7. Forbindelse ifølge krav 6, der er valgt fra (5)-l-(4-(2-(difluormethyl)pyridin-4-yl)-2-(trifluormethyl)phenoxy)-2,4-dimeth ylpentan-2-amin; (S) -2,4-dimethyl-l-(4-(2-methylpyridin-4-yl)-2-(trifluormethyl)phenoxy)pentan-2-amin; (5)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-6-methyl-[2,4'-bipyridin]-2'-yl)carbamat; (5)-l-((4-(difluormethyl)-2'-meth yl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-l-((2',6-bis(difluormethyl)-[2,4'-bipyridin] -5-yl)oxy)-2,4-dimeth ylpentan-2-amin; (5)-2,4-dimethyl-l-((2'-methyl-4-(trifluormethyl)-[2,4'-bipyridin]-5-yl)oxy)pentan-2-amin; (5)-l-((4-(difluormethyl)-3'-fluor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((6-(difluormethyl)-3'-fluor-2'-methyl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; (5)-l-((3-(difluormethyl)-5-(2-methylpyrimidin-4-yl)pyridin-2-yl)oxy)-2,4-dimeth ylpentan-2-amin og (5)-l-((4-chlor-2'-meth yl-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimeth ylpentan-2-amin; eller et farmaceutisk acceptabelt salt deraf.
  8. 8. Forbindelse med formlen (II) (Π),
    eller et farmaceutisk acceptabelt salt deraf, hvor: A er valgt fra
    hvor
    ' betegner bindingspunktet til B; B er valgt fra phenyl og pyridinyl; R1 er valgt fra hydrogen, difluormethyl, halo, methoxy, methyl, -NHC(O)CH3, -NHCO2CH3 og trifluormethyl; R2 er valgt fra hydrogen, -CH2OH og halo;
    R3 er valgt fra hydrogen, cyano, cyclopropyl, difluormethyl, halo, hydroxymethyl, methoxy, methyl, trifluormethoxy, trifluormethyl og en femleddet aromatisk ring, der indeholder ét, to eller tre heteroatomer valgt fra nitrogen, oxygen og svovl; R4 er valgt fra hydrogen, halo og methyl; og R5 er valgt fra hydrogen, ethyl, fluormethyl, difluormethyl, methyl og trifluormethyl.
  9. 9. Forbindelse ifølge krav 7, der er (5)-l-((2',6-bis(difluormethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin; eller et farmaceutisk acceptabelt salt deraf.
  10. 10. Sammensætning, der omfatter en farmaceutisk acceptabel mængde af en forbindelse ifølge et hvilket som helst af kravene 1 til 9, eller et farmaceutisk acceptabelt salt deraf, og en farmaceutisk acceptabel bærer.
  11. 11. Forbindelse ifølge et hvilket som helst af kravene 1 til 9, eller et farmaceutisk acceptabelt salt deraf til anvendelse i behandling eller håndtering af en sygdom eller en forstyrrelse medieret af AAK1-aktivitet.
  12. 12. Forbindelse eller farmaceutisk acceptabel salt deraf til anvendelse ifølge krav 11, hvor sygdommen eller forstyrrelsen er valgt fra Alzheimers sygdom, bipolar forstyrrelse, smerte, Parkinsons sygdom og skizofreni.
  13. 13. Forbindelse eller farmaceutisk acceptabel salt deraf til anvendelse ifølge krav 12, hvor smerten er neuropatisk smerte.
  14. 14. Forbindelse eller farmaceutisk acceptabel salt deraf til anvendelse ifølge krav 13, hvor den neuropatiske smerte er fibromyalgi eller perifer neuropath
DK15717342.8T 2014-04-02 2015-04-01 Biarylkinasehæmmere DK3126351T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973942P 2014-04-02 2014-04-02
US201462061591P 2014-10-08 2014-10-08
PCT/US2015/023805 WO2015153720A1 (en) 2014-04-02 2015-04-01 Biaryl kinase inhibitors

Publications (1)

Publication Number Publication Date
DK3126351T3 true DK3126351T3 (da) 2019-01-14

Family

ID=52988448

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15717342.8T DK3126351T3 (da) 2014-04-02 2015-04-01 Biarylkinasehæmmere

Country Status (27)

Country Link
US (7) US9902722B2 (da)
EP (1) EP3126351B1 (da)
JP (1) JP6411541B2 (da)
KR (1) KR102379518B1 (da)
CN (1) CN106458994B (da)
AU (1) AU2015240869B2 (da)
BR (1) BR112016022298B1 (da)
CA (1) CA2944466C (da)
CL (1) CL2016002502A1 (da)
CY (1) CY1120988T1 (da)
DK (1) DK3126351T3 (da)
EA (1) EA028942B1 (da)
ES (1) ES2700549T3 (da)
HR (1) HRP20181899T1 (da)
HU (1) HUE041457T2 (da)
IL (1) IL248086B (da)
LT (1) LT3126351T (da)
MX (1) MX2016012829A (da)
PE (1) PE20170004A1 (da)
PL (1) PL3126351T3 (da)
PT (1) PT3126351T (da)
RS (1) RS58062B1 (da)
SG (1) SG11201608195QA (da)
SI (1) SI3126351T1 (da)
SM (1) SMT201800665T1 (da)
WO (1) WO2015153720A1 (da)
ZA (1) ZA201606767B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006100A1 (en) 2013-07-08 2015-01-15 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
PT3105218T (pt) 2014-02-13 2019-12-05 Incyte Corp Ciclopropilaminas como inibidores de lsd1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
DK3105226T3 (da) 2014-02-13 2019-10-14 Incyte Corp Cyclopropylaminer som lsd1-inhibitorer
KR102379518B1 (ko) * 2014-04-02 2022-03-25 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
EP3292124B1 (en) * 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
US10544120B2 (en) * 2015-10-01 2020-01-28 Bristol-Myers Squibb Company Biaryl kinase inhibitors
ES2767776T3 (es) * 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
TW202120495A (zh) * 2019-08-02 2021-06-01 美商愛彼特生物製藥股份有限公司 經取代環丙基—２，２＇—聯嘧啶基化合物、其類似物及其使用方法
US11730723B2 (en) 2020-04-21 2023-08-22 Lexicon Pharmaceuticals, Inc. Compounds and methods for treating viral infections
CA3175973A1 (en) 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
CN115697968B (zh) * 2020-05-28 2024-03-29 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
TW202210461A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種（ｓ）—２—胺基—３—（４—（２，３—二甲基吡啶—４—基）苯基）丙酸甲酯二酸鹽的製備方法
CN117715899A (zh) * 2021-07-15 2024-03-15 西藏海思科制药有限公司 Aak1抑制剂及其用途
WO2023051749A1 (zh) * 2021-09-30 2023-04-06 武汉人福创新药物研发中心有限公司 Aak1抑制剂及其用途
WO2023167806A1 (en) 2022-03-01 2023-09-07 Lexicon Pharmaceuticals, Inc. Methods and compounds useful in the sythesis of an aak1 inhibitor
US12344596B2 (en) * 2022-03-01 2025-07-01 Lexicon Pharmaceuticals, Inc. Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof
EP4496788A1 (en) 2022-03-23 2025-01-29 Teva Pharmaceuticals International GmbH Solid state forms of lx9211 and salts thereof
CN120202001A (zh) * 2022-11-10 2025-06-24 西藏海思科制药有限公司 一种含aak1抑制剂的药物组合物
CN120344529A (zh) * 2022-12-13 2025-07-18 上海海雁医药科技有限公司 杂环取代的五并六元杂芳基衍生物、其药物组合物及应用与制备方法
CN120641406A (zh) * 2023-01-16 2025-09-12 上海海雁医药科技有限公司 杂环取代的含氮杂环衍生物、其药物组合物及应用与制备方法
CN118772152A (zh) * 2023-04-07 2024-10-15 艾立康药业股份有限公司 作为aak1抑制剂的氮杂环类化合物
WO2024207945A1 (zh) * 2023-04-07 2024-10-10 艾立康药业股份有限公司 作为aak1抑制剂的氮杂环类化合物
WO2025092928A1 (zh) * 2023-11-02 2025-05-08 西藏海思科制药有限公司 一种可抑制连接蛋白相关激酶1的化合物、制备及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003286895A1 (en) 2002-11-05 2004-06-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
WO2005085227A1 (en) * 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
AU2007238897A1 (en) * 2006-04-12 2007-10-25 Wyeth Anilino-pyrimidine phenyl and benzothiophene analogs
EP2121613A2 (en) * 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors
HUE036040T2 (hu) * 2012-03-09 2018-06-28 Lexicon Pharmaceuticals Inc Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
JP2016509066A (ja) 2013-02-22 2016-03-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アダプター関連キナーゼ１（ａａｋ１）の阻害剤としての５ｈ−クロメノ［３，４−ｃ］ピリジン
WO2015006100A1 (en) 2013-07-08 2015-01-15 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
WO2015038112A1 (en) 2013-09-11 2015-03-19 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
EP3099300B1 (en) 2014-01-29 2018-09-05 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
ES2701903T3 (es) 2014-01-31 2019-02-26 Bristol Myers Squibb Co Inhibidores de cinasa a base de quinolina
KR102379518B1 (ko) * 2014-04-02 2022-03-25 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
EP3200797A1 (en) 2014-09-30 2017-08-09 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
EP3292124B1 (en) 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
ES2767776T3 (es) 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
US10544120B2 (en) * 2015-10-01 2020-01-28 Bristol-Myers Squibb Company Biaryl kinase inhibitors
US10981190B2 (en) 2018-07-06 2021-04-20 Liqui-Box Corporation Dispensing probe for dispensing flowable material

Also Published As

Publication number Publication date
PL3126351T3 (pl) 2019-03-29
CA2944466A1 (en) 2015-10-08
BR112016022298A2 (da) 2017-08-15
CY1120988T1 (el) 2019-12-11
BR112016022298B1 (pt) 2022-09-20
RS58062B1 (sr) 2019-02-28
US12065437B2 (en) 2024-08-20
PE20170004A1 (es) 2017-03-04
US10351563B2 (en) 2019-07-16
CA2944466C (en) 2020-06-09
US20190048006A1 (en) 2019-02-14
US10981910B2 (en) 2021-04-20
US20170183340A1 (en) 2017-06-29
IL248086B (en) 2019-09-26
US20240360131A1 (en) 2024-10-31
EA201691916A1 (ru) 2017-02-28
PT3126351T (pt) 2018-12-04
LT3126351T (lt) 2018-11-26
CN106458994A (zh) 2017-02-22
US20210277001A1 (en) 2021-09-09
JP6411541B2 (ja) 2018-10-24
AU2015240869B2 (en) 2018-11-08
WO2015153720A1 (en) 2015-10-08
HUE041457T2 (hu) 2019-05-28
MX2016012829A (es) 2017-01-05
EP3126351B1 (en) 2018-09-19
AU2015240869A1 (en) 2016-11-17
KR20160132491A (ko) 2016-11-18
ES2700549T3 (es) 2019-02-18
US10155760B2 (en) 2018-12-18
ZA201606767B (en) 2018-05-30
CN106458994B (zh) 2019-09-13
SG11201608195QA (en) 2016-10-28
US20190367508A1 (en) 2019-12-05
IL248086A0 (en) 2016-11-30
HRP20181899T1 (hr) 2019-01-11
KR102379518B1 (ko) 2022-03-25
US20180134704A1 (en) 2018-05-17
SMT201800665T1 (it) 2019-01-11
CL2016002502A1 (es) 2017-06-23
EP3126351A1 (en) 2017-02-08
EA028942B1 (ru) 2018-01-31
US10723734B2 (en) 2020-07-28
JP2017511329A (ja) 2017-04-20
US9902722B2 (en) 2018-02-27
NZ725814A (en) 2021-06-25
SI3126351T1 (sl) 2018-11-30
US20200317671A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
US12065437B2 (en) Biaryl kinase inhibitors
KR102704295B1 (ko) 비아릴 키나제 억제제
US10174044B2 (en) Fused pyridines as kinase inhibitors
NZ725814B2 (en) Biaryl kinase inhibitors
HK1231070A1 (en) Biaryl kinase inhibitors
HK1231070B (en) Biaryl kinase inhibitors